Equities

Tasly Pharmaceutical Group Co Ltd

600535:SHH

Tasly Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)13.95
  • Today's Change-0.17 / -1.20%
  • Shares traded8.34m
  • 1 Year change+0.14%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3,9264,0523,592
Total Receivables, Net2,1633,3943,845
Total Inventory1,7481,5321,548
Prepaid expenses719065
Other current assets, total826191199
Total current assets8,7339,2599,249
Property, plant & equipment, net3,8123,9894,168
Goodwill, net1616167
Intangibles, net2,0271,5871,626
Long term investments2,0541,5111,229
Note receivable - long term------
Other long term assets------
Total assets16,71416,47816,542
LIABILITIES
Accounts payable444592531
Accrued expenses192248217
Notes payable/short-term debt944484387
Current portion long-term debt/capital leases521529399
Other current liabilities, total269281322
Total current liabilities2,3702,1351,855
Total long term debt1,4961,4511,116
Total debt2,9602,4651,902
Deferred income tax0.112342
Minority interest322265333
Other liabilities, total159178215
Total liabilities4,3464,0523,560
SHAREHOLDERS EQUITY
Common stock1,5001,5001,513
Additional paid-in capital9581,4391,530
Retained earnings (accumulated deficit)9,9299,38210,222
Treasury stock - common(106)(106)(251)
Unrealized gain (loss)5.21141--
Other equity, total8370(32)
Total equity12,36812,42612,981
Total liabilities & shareholders' equity16,71416,47816,542
Total common shares outstanding1,4941,4941,499
Treasury shares - common primary issue5.755.7514
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.